IL6 and rheumatoid arthritis: EGCG therapy reduces the production of IL-1 and IL-6 by synovial fibroblasts in RA patients while enhancing the activity of the soluble glycoprotein gp130 receptor inhibitor, which in turn inhibits IL-6 trans-signaling [33].